CDTX News and Press, Cidara Therapeutics Inc. From 10/04/22

The shares of clinical-stage biotech Cidara Therapeutics ( NASDAQ: CDTX ) gained over 8% pre-market Tuesday after the company announced that British drugmaker Mundipharma paid $11.1M as a milestone payment under a 2019 licensing deal. The payment follows the acceptance...

Milestone payment triggered by European Medicines Agency acceptance of marketing authorization application for rezafungin Company eligible to receive up to an additional $108M in milestones from multiple existing partnerships based on successful completion of activities planned ...

SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA)...

Cidara Therapeutics ( NASDAQ: CDTX ) said it began dosing in a phase 2a trial of CD388 to evaluate the pre-exposure prophylactic activity of the antiviral against influenza virus. CD388 is aimed to deliver universal prevention of seasonal and pandemic influenza, t...

CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak ® platform designed to help transform the standard of care for seasonal and pandemic influenza prevention Study is being conducted in collaboration with Janssen SAN DIEGO, Sept. 13, 2022 (G...

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief E...

Cidara Therapeutics press release ( NASDAQ: CDTX ): Q2 GAAP EPS of -$0.19 beats by $0.09 . Revenue of $6.22M (-81.1% Y/Y) beats by $0.01M . For further details see: Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M ...

SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended Jun...

Cidara Therapeutics ( NASDAQ: CDTX ) said it filed for U.S, approval of rezafungin to treat a type of fungal infection called invasive candidiasis and also granted Melinta Therapeutics ( OTCPK:MLNTQ ) an exclusive license to commercialize rezafungin in the...

Submitted NDA for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on July 22, 2022, with an anticipated PDUFA target action date in the first quarter of 2023, if accepted for review following application validation Melinta acquires exclusive rights to commerci...